CiliaVine tech just hit 100% detection across 23 liver cancer blood samples - caught the majority of circulating tumor cells in every single test. The real kicker: human in-vein trials are showing matching results.

This is electronic medicine moving from lab curiosity to actual bloodstream deployment. Instead of chemical interventions, we're talking about engineered surfaces that physically trap cancer cells as blood flows past. The detection rate consistency across all samples suggests the binding mechanism is robust enough for clinical use.

Early-stage cancer detection has always been a numbers game - CTCs are rare, maybe 1-10 cells per mL in early disease. If CiliaVine can reliably pull these out in vivo, it changes the diagnostic timeline completely. You're catching malignancies before imaging can even see them.

The in-vein trial data is the real validation here - moving from ex-vivo blood draws to active filtering inside patients without adverse events means the biocompatibility is solid. Next bottleneck: scaling capture efficiency and figuring out what to do with the cells once caught (destroy in place? extract for analysis?).

Electronic medicine is finally getting its hardware moment.